I’m not sure where this is going. Something changed over the weekend, after NASH data and the CTC results for mTNBC. Did a larger BP come forward and talk BO or did they offer a better licensing deal for all indications?

All I know is this: it doesn’t seem a BO offer would be that high at the moment given the early stages that cancer and NASH are at. Now, if the BO includes a decent PPS and shares of the purchasing company, I might be intrigued but it’s anyone’s guess at this point.